نتائج البحث

Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease

• Authors : Can Chen; Yang Fan; Ying Xu

Subjects: Acute myeloid leukaemia; allogeneic hematopoietic stem cell transplantation; conditioning regimen

• Source: Annals of Medicine, Vol 57, Iss 1 (2025)

تفاصيل العنوان

Resiquimod induces a mixed Th1 and Th2 response via STAT1 and STAT3 signalling in chickens

• Authors : Deepthi Kappala; Saravanan Ramakrishnan; Patel Nikunjkumar Prakashbhai

Subjects: Resiquimod; Toll-like receptor signalling; Chicken

• Source: Biochemistry and Biophysics Reports, Vol 41, Iss , Pp 101941- (2025)

تفاصيل العنوان

Unraveling a novel therapeutic facet of Etravirine to confront Hepatocellular Carcinoma via disruption of cell cycle.

• Authors : Nair, Gouri¹ (AUTHOR); Saraswathy, G. R.² (AUTHOR); Aranjani, Jesil Mathew³ (AUTHOR)

• Source: Scientific Reports. 2/10/2025, Vol. 15 Issue 1, p1-23. 23p.

تفاصيل العنوان

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

• Authors : Krzysztof Kalwak; Laura M. Moser; Ulrike Pötschger

Subjects: Specialties of internal medicine; RC581-951

• Source: Blood Advances, Vol 9, Iss 4, Pp 741-751 (2025)

تفاصيل العنوان

Haploidentical stem cell transplantation with posttransplant cyclophosphamide in children with Wiskott–Aldrich syndrome: a case report

• Authors : Le Nguyen Ngoc Quynh; Binh Nguyen Thanh; Lien Luong Thi

Subjects: Wiskott–Aldrich syndrome; thrombocytopenia; inborn error immunity

• Source: Frontiers in Immunology, Vol 16 (2025)

تفاصيل العنوان

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry

• Authors : Frederick L Locke; Grant Schofield; Marcelo Pasquini

Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282

• Source: Journal for ImmunoTherapy of Cancer, Vol 13, Iss 2 (2025)

تفاصيل العنوان

New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers.

• Authors : Battaglia, Giulia¹ (AUTHOR) ; Lazzarotto, Davide¹ (AUTHOR) ; Tanasi, Ilaria² (AUTHOR)

Subjects: *ACUTE myeloid leukemia; *INDUCTION chemotherapy; *OVERALL survival

• Source: Journal of Clinical Medicine. Feb2025, Vol. 14 Issue 3, p700. 10p.

تفاصيل العنوان

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

• Source: A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

تفاصيل العنوان

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (aMMbition)

• Source: A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and

تفاصيل العنوان

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

• Authors : National Cancer Institute (NCI)

• Source: Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

تفاصيل العنوان